SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it is hosting a “Pharmacogenetics, Clinical Development and Tailored Therapies” workshop at the Discovery 2 Diagnostics Conference in Philadelphia. The workshop will focus on how researchers can use genetic information to improve drug development and will include new information on using the SNP Array 6.0 to discover unknown investigative biomarkers, as well as the DMET Panel to directly assay valid biomarkers of drug metabolism.
